# Cell-free systems & cell-free bioproduction Cell-free protein synthesis (CFPS) bypasses the living cell: ribosomes and translation factors in a reaction tube deliver the target protein in hours, not weeks, with toxic and non-canonical amino acids incorporated. Source: https://en.bioecon.ru/technology/cell-free-systems-cell-free-bioproduction/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: Industrial Biotechnology & Synthetic Biology Roadmap | OECD: Industrial Biotechnology | Regulator: FDA (USA), EMA (EU), NMPA (China)] Cell-free systems (Cell-Free Protein Synthesis, CFPS) are a paradigm that dispenses with the living host cell in industrial synthesis: only the molecular translation machines (ribosomes, tRNAs, initiation/elongation/termination factors) are extracted from organisms and assembled in a reaction tube with a DNA template, amino acids and an ATP-regeneration system. A living cell spends up to 80% of its resources on its own metabolism; a cell-free system directs all activity to the product, cutting synthesis from weeks to hours and enabling proteins toxic to cells as well as non-canonical amino-acid incorporation. Key platforms of cell-free production: 1. **Cell-lysate CFPS (Cell Lysate CFPS):** E. coli, CHO, wheat-germ extracts — a ready translation complex. 2. **Reconstituted PURE (PURE):** 36 purified E. coli enzymes, no endogenous proteases — absolute purity. 3. **Enzymatic cascades (Cell-Free Cascades):** 10–20 thermostable enzymes turn sugars into chemicals without a cell. 4. **Paper sensors (Paper TX-TL):** lyophilised TX-TL + riboswitches for field diagnostics. ### Sectoral value chain ``` [producer culture] ──> [lysis & centrifugation] ──> [lysate] │ (DNA + ATP cascade) │ ▼ [target protein] <─── [affinity purification] <─── [in-vitro synthesis, hours] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Lysate Production** | cell cultivation, lysis, ribosome/enzyme isolation | **In:** cells, homogenisers. **Out:** standardised lysate. | | **Energy Formulation** | ATP-regeneration buffer (phosphoenolpyruvate/glucose) | **In:** cofactors, amino acids. **Out:** energy mix. | | **DNA Template** | de novo synthesis/amplification with a T7 promoter | **In:** digital gene design. **Out:** DNA template. | | **In-Vitro Synthesis** | mixing lysate, buffer, template at +30–37°C | **In:** lysate, buffer, template. **Out:** reaction mix. | | **Purification** | affinity chromatography and filtration | **In:** reaction mix. **Out:** pure protein. | | **On-Demand Distribution** | lyophilised kits for on-the-spot synthesis | **In:** lyophilate, cartridges. **Out:** on-site kits. | Cross-cutting technologies of the sector: - **Cheap-substrate ATP regeneration:** 10–12-enzyme cascades on glucose/starch cut energy cost 100×. - **Non-canonical amino acids (nSAA):** re-assigning tRNA/synthetases to incorporate artificial amino acids (ADC, click chemistry). - **Continuous-flow microfluidic reactors:** continuous substrate feed and inhibitor removal — day-long synthesis. --- ## US The US leads CFPS commercialisation for therapeutic proteins and RNA pesticides (DARPA, VC). ### Sutro, GreenLight, Jewett Lab, DARPA on-demand pharmacy - **Sutro Biopharma:** XpressCF® platform on E. coli/CHO lysate — antibodies and ADCs, reactors to thousands of litres. - **GreenLight Biosciences:** cell-free dsRNA and mRNA synthesis (agro-pesticides, vaccines) by the tonne. - **DARPA On-Demand Pharmacy + Jewett Lab (Northwestern):** portable synthesis suitcases from lyophilised cartridges. --- ## CN China bets on large-scale cell-free enzymatic cascades (CAS, TIB). ### TIB CAS, cell-free starch from CO2, cascade biocatalysis - **TIB CAS (ASAP):** an 11-enzyme cascade synthesises starch from CO2/H2 — 8.5× maize photosynthesis. - **Multi-step biocatalysis:** rare sugars (allulose, tagatose), inositol, amino acids without live GMOs. - **National key R&D program:** immobilised enzymes for continuous industrial reactors. --- ## EU The EU leads in high-purity PURE systems and safety standards for cell-free output. ### PUREfrex (GeneFrontier), Horizon Europe, Max Planck/CNRS - **PUREfrex (GeneFrontier):** reconstituted system of 36 enzymes — protein screening free of bacterial LPS. - **Horizon Europe:** microfluidic/membrane reactors for food and textile enzymes. - **Max Planck/CNRS:** artificial cells — cell-free systems in lipid vesicles. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Sutro Biopharma** | 🇺🇸 USA | *XpressCF®* (CDMO) | CHO/E. coli CFPS to thousands of L; toxic proteins, ADCs | Commercial | | **GreenLight Biosciences** | 🇺🇸 USA | cell-free RNA platforms | enzymatic dsRNA/mRNA synthesis by the tonne | Commercial | | **GeneFrontier** | 🇯🇵 Japan | *PUREfrex®* | 36 purified enzymes, no proteases | Commercial | | **TIB CAS** | 🇨🇳 China | *ASAP* (starch from CO2) | 11-enzyme cascade, 8.5× photosynthesis | Research | | **Swiftscale Biotherapeutics** | 🇺🇸 USA | rapid CFPS | DNA→protein in 24 h (personalised oncology) | Scaling | | **Northwestern University** | 🇺🇸 USA | *on-demand* TX-TL kits | paper/cartridge lyophilisation (Jewett Lab) | Research | --- ## Tech stack and innovations The stack rests on PURE, cheap ATP regeneration and genetic-code expansion. 1. **PURE (reconstituted translation):** - 36 purified E. coli enzymes + 70S ribosomes; no proteases/nucleases → absolute-purity proteins. 2. **Cheap-substrate ATP cascades:** - maltodextrin phosphorylase + a starch/glucose cascade — ATP regeneration 100× cheaper. 3. **Genetic-code expansion:** - RF1-free lysates (C321.∆A) — amber codon for a non-canonical amino acid (p-azidophenylalanine) for ADC click chemistry. --- ## Value chains and production pipelines ### Industrial pipeline of cell-free ADC synthesis (XpressCF, ISO 9001 / cGMP) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. CHO lysate (XpressCF) │ ───> │ 2. Reaction with DNA + nSAA│ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Affinity Ab purification│ <─── │ 3. In-vitro synthesis, 10 h│ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Click chemistry w/ toxin│ ───> │ 6. Filtration, QC, fill │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: CHO lysate CHO are grown in a cGMP reactor, detergent lysis, 30,000 g centrifugation, own-mRNA removal with micrococcal nuclease. #### Stage 2: Reaction mix The reactor is loaded with lysate, antibody DNA template, energy buffer, amino acids and the non-canonical amino acid (pAMF) at the UAG codon. #### Stage 3: Cell-free synthesis At +32°C, continuous substrate feed and inhibitor dialysis; T7 translation yields the modified antibody in 10 h at 2.5 g/L. #### Stage 4: Affinity purification Protein A Sepharose binds the antibody; elution at pH 3.0, neutralisation to pH 7.2. #### Stage 5: Click chemistry DBCO-linker-toxin (MMAE) reacts with the antibody azide groups in 2 h; fixed DAR = 2.0. #### Stage 6: Final control Sterile 0.22 µm filtration, lyophilisation, MALDI-TOF DAR control, sterility and pyrogen testing.